FamiCordTx
is a biotech company focused on developing cell & gene therapies to patients and doctors worldwide. One of our projects aims to create the world's first CAR-T cancer therapy ready for immediate administration, based on an allogeneic populational bank.
FamiCordTx
FamiCordTx has been operating since 2019 and is part of the international FamiCord capital group, which boasts over 20 years of history.
CAR-T is a groundbreaking technology combining cell therapy and genetic engineering. Patients with hematological cancers have the chance to be treated with T lymphocytes, which, after genetic modification, become tools of the most advanced immunotherapy available today.
Mission
Our mission is to make advanced gene and cell therapies accessible for everyone, improving patients’ health and lives. We tirelessly pursue this goal, striving to provide doctors with new possibilities and patients with hope and a chance for better tomorrow.
We are ready to change the therapeutic landscape together. What was once unattainable, we believe can become reality through the development of our innovative technologies and bring revolution to cancer treatment and beyond.
Yesterday is a history, tomorrow is a mystery, but today is a gift, that’s why it is called the present. We persistently strive to give our patients this gift on every tomorrow...
People
FamiCordTx is about people.
Our outstanding scientifc team combines experience and expertise gained across the globe—from the United States to Australia, centred in Poland. We collaborate with world-class scientists and clinicians. Our company also includes a dedicated team specializing in project management, clinical research, and administrative professionals. Together, we form a team capable of effectively implementing cutting-edge cell and gene technologies under the stringent GMP standards required for drug manufacturing.